Skip to Content

'
Edward Sanghyun Kim, M. D.

Present Title & Affiliation

Primary Appointment

Chief, Section of Head and Neck Medical Oncology, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Clinical Research Operations, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Co-Director, Educational Programs, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3016
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1996 Northwestern University, Chicago, IL, MD, Honors Program in Medical Education (HPME)
1992 Northwestern University, Evanston, IL, BS, Systems Biology, Honors Program in Medical Education (HPME: 7 yr Medical Program)

Postgraduate Training

1999-2001 Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Waun Ki Hong, M. D., Chairman and Division Head; Robert Wolf, M. D., Fellowship Director
1996-1999 Clinical Fellowship, Baylor College of Medicine, Houston, TX, Andrew Schafer, M. D., Chairman; Edward Lynch, M. D. Residency Director

Experience/Service

Other Appointments/Responsibilities

Editorial Board Member; Clinical Cancer Research, Journal of Clinical Oncology, Alexandria, VA, 2010-present

Institutional Committee Activities

Co-Chairman, Committee, Radiation Therapy Oncology Group (RTOG), 2001-present

Honors and Awards

2010 Plenary Presentation - BATTLE Trial, American Association for Cancer Research, Washington, D. C., April 2010

Selected Publications

Peer-Reviewed Original Research Articles
1. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Molecular Predictors of Outcome with Gefitinib and Docetaxel in Previously Treated Non-Small Cell Lung Cancer: Data from the Randomized Phase III INTEREST Trial. Jour Clin Onc 23(3445):1-7, 12/2009. PMID: 20038723.
2. William WN JR, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting Stage IIIB and IV Non-Small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology and End Results. CHEST 136(3):701-9, 9/2009. PMID: 19318668.
3. Liao A, Komaki RR, Thames HD, Liu HH, Tucker SL, Mogan R. Martel MK, Wei X, Fossella F, Kim ES, Cox JD. Influence of technological advances on outcomes in patients with unresectable locally advanced non-small cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76(3):775-781, 6/2009. PMID: 19515503.
4. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Geng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A Phase II Study of Lonafarnib (SCH66336) in patients with chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol 32(3):274-279, 5/2009. PMID: 19433965.
5. Gold KA, Lee HY, Kim, ES. Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck. Cancer 1:115(5):922-35, 5/2009. PMID: 19346943.
6. Kim ES, Mauer AM, William Jr. WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase II study of cetuximab in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Cancer 115(8):1713-22, 4/2009. PMID: 19208430.
7. Papadimitrakopoulou VA, Lee JJ, William Jr, WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid versus retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 1(27(4)):599-604, 2/2009. PMID: 19075276.
8. Kim ES, Watkins CL, Armur AA, Douillard JY. Gefitinib plus docetaxel in non-small-cell lung cancer. The Lancet 373 (9663):542, 2009.
9. William Jr., WN, Lippman, Martin JW, Tran HT, Sabichi AL, Kim ES, Feng L, Lee JJ, Papadimitrakopoulou VA. Phase II chemoprevention Trial with High Dose Fenretinide for Oral Pre-Malignant Lesions. Cancer Prevention Research 2:22-26, 2009. PMID: 19139014.
10. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in surviving expression. Clin Cancer Res 14(5):1581-9, 3/2008. PMID: 18316583.
11. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin; a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26(3):354-60, 1/2008.
12. Zhou X, Liu S, Kim ES. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 5(3):181-93, 2008.
13. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu HL, Long-Yun L, Watkins,CL, Sellers MV, Lowe ES, Sun Yan, Liao ML, Osterline K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small cell lung cancer: a randomized phase III trail (INTEREST). The Lancet 273(9652):1809-18, 2008. PMID: 19027483.
14. Bhutani M, Pathank AK, Fan Y-H, Liu D, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prevention Research 1:39-44, 2008. PMID: 19138934.
15. Zheng S, El-Naggar AK, Kim ES, Jurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 26(48):6896-6904, 10/2007. PMID: 17486075.
16. Kim ES, Bosquee L. The importance of accurate lymph node staging in early and locally advanced non-small cell lung cancer; an update on available techniques. J Thorac Oncol Suppl 2S:59-67, 6/2007. PMID: 17589301.
17. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610-621, 5/2007. PMID: 17522250.
18. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 1:13(9)(9). e-Pub 5/2007. PMID: 17473213.
19. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of surviving expression counteract the antitumor action of erlotinib. Cancer Res 66(20):10100-11, 10/2006. PMID: 17047074.
20. Khuri FR, Lee JJ, Lippman SM, Kim ES, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong RK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. Journal of the National Cancer Institute 98(7):441-450, 4/2006. PMCID: PMC16595780.
21. Kim ES, Johnson ED. Novel combinations with docetaxel in the treatment of non-small-cell lung cancer. Clin Lung Cancer 7 Suppl 3:S83-6, 12/2005. PMID: 16384541.
22. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005. PMID: 16258975.
23. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104(3):561-9, 8/2005. PMID: 16028213.
24. Seixas-Silva, Jr., Jose A., Kim ES. Phase II Bioadjuvant Study of InterferonAlfa-2a, Isotretinoin, and Vitamin E in Local Advanced Squamous Cell Carcinoma of the Head and Neck. American Medical Association. e-Pub 4/2005.
25. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Hypoxia-inducible factor 1a and antiangiogenic activityof farnesyl transferase inhibitor SCH66336 in human aerodigestive tract cancer. Journal of the National Cancer Institute 97 (17):1272-1286, 2005.
26. Lee HY, Kim ES. Implication of hypoxia-inducible factor-1a in antiangiogenic activity of farnesyl transferase inhibitor SCH66336 in human aerodigestive tract cancer. Jrnl Natl Cancer Institute, 2005.

Invited Articles
1. Gold KA, Kim ES. Molecular markers and gene profiling in head and neck cancer. Curr Opin Oncol 21(3):206-11, 5/2009. PMCID: PMC19346943.
2. William Jr, WN, Heymach JV, Lippman SM.Kim ES,. Molecular Targets for Cancer Chemotherapy. Nature Reviews Drug Discovery 8(3):213-25, 3/2009. PMID: 19247304.

Editorials
1. William WN, Gold K, Kim ES. Gefitinib for advanced non-small cell lung cancer and quality of life: expending and improving treatment options. Annals of Oncology 20(9):1455-1457, 2/2010.

Abstracts
1. Kim ES, Herbst RS, Lee JJ, Blumenschein Jr. GR, Tsao A, Alden CM, Tang X, Liu S, Stewart DJ, Heymach JV, Tran HT, Hicks ME, Erasmus Jr. E, Gupta, S, Powis G, Lippman SM, Wistuba II, Hong WK. The BATTLE Trial (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination): Personalizing Therapy for Lung Cancer. Proceedings of AACR (LBA-1), 4/2010.

Grant & Contract Support

Title: Institutional National Research Science Award (T32); Training of Academic Head and Neck Surgical Oncologist
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Dr. Jeffrey Myers
Duration: 7/1/2011 - 6/30/2016
 
Title: BATTLE-2: Personalizing Non-Small Cell Lung Cancer (NSCLC) Therapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Roy Herbst
Duration: 4/1/2011 - 3/31/2016
 
Title: Personalizing Medicine: The Identification of Biomarkers for Predicting Response to Treatment in Advanced Non-Small Cell Lung Cancer
Funding Source: V Foundation
Role: Co-Investigator
Principal Investigator: Ignacio I Wistuba
Duration: 10/1/2010 - 9/30/2013
 
Title: Mutation Analysis of Squamous Cell Carcinoma of the Lung
Funding Source: AstraZeneca
Role: Co-Investigator
Principal Investigator: Ignacio I. Wistuba
Duration: 9/1/2010 - 8/31/2011
 
Title: Molecular Profiles for Lung Cancer Pathogenesis and Detection in U.S. Veterans
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Ignacio I. Wistuba
Duration: 7/1/2010 - 6/30/2014
 
Title: U10 Full Membership Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Roy Herbst
Duration: 1/1/2010 - 12/31/2016
 
Title: PROSPECT
Funding Source: Department of Defense (DOD)
Role: Co-Principal Investigator
Principal Investigator: Waun Ki Hong
Duration: 6/1/2007 - 5/31/2011
 
Title: BATTLE (Biomarker-based approaches of targeted therapy for lung cancer elimination)
Funding Source: Department of Defense (DOD)
Role: Co-Principal Investigator
Principal Investigator: Waun Ki Hong
Duration: 4/1/2006 - 4/30/2011
 
Title: IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches and Molecular Targets and Complementary, Innovative and Therapeutic Modalities)
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Waun K. Hong
Duration: 2/1/2005 - 3/1/2011
 
Title: VITAL (Vanguard Trial of Investigational Therapeutics in Adjuvant Treatment of Lung Cancer)
Funding Source: Department of Defense (DOD)
Role: Co-Principal Investigator
Principal Investigator: Waun Ki Hong
Duration: 12/15/2004 - 1/14/2011

Last updated: 10/14/2010